中国医科大学学报
中國醫科大學學報
중국의과대학학보
JOURNAL OF CHINA MEDICAL UNIVERSITY
2001年
1期
56-58
,共3页
李军%刘贤奎%孔垂泽%刘同才%何三光%杨涛%袁中旗
李軍%劉賢奎%孔垂澤%劉同纔%何三光%楊濤%袁中旂
리군%류현규%공수택%류동재%하삼광%양도%원중기
肾肿瘤%输尿管肿瘤%癌%基因,p53%nm23
腎腫瘤%輸尿管腫瘤%癌%基因,p53%nm23
신종류%수뇨관종류%암%기인,p53%nm23
目的:揭示p53、nm23 基因表达与肾盂输尿管癌生物学行为的关系。 方法:采用免疫组化SABC法和原位杂交技术检测p53、nm23的表达。结果:肾盂输尿管癌p53、nm23阳性表达分别为51.1%(23/45)和 46.7%(21/45)。p53阳性表达T2-T3为60%(21/35),T1为20%(2/10),P<0.05;G2-G3为59.0%(23/39),G1为0%(0/6)。nm23阳性表达T2-T3为48.6%(17/35),T1为40%(4/10),P>0.05,G2-G3为 48.7%(19/39),G1为33.3%(2/6),P>0.05。p53阳性表达术后再发膀胱癌与阴性表达相比较P>0.05。nm23阳性表达术后膀胱癌再发为61.9%(13/21),阴性表达为20.8%(5/24), P< 0.01。p53、nm23阳性表达生存率明显低于阴性表达,P<0.05。结论:p53 阳性表达与肾盂输尿管癌病理分期、分级有关,nm23阳性表达与术后再发膀胱癌有关。p53和nm23可能是判断肾盂输尿管癌预后的指标之一。
目的:揭示p53、nm23 基因錶達與腎盂輸尿管癌生物學行為的關繫。 方法:採用免疫組化SABC法和原位雜交技術檢測p53、nm23的錶達。結果:腎盂輸尿管癌p53、nm23暘性錶達分彆為51.1%(23/45)和 46.7%(21/45)。p53暘性錶達T2-T3為60%(21/35),T1為20%(2/10),P<0.05;G2-G3為59.0%(23/39),G1為0%(0/6)。nm23暘性錶達T2-T3為48.6%(17/35),T1為40%(4/10),P>0.05,G2-G3為 48.7%(19/39),G1為33.3%(2/6),P>0.05。p53暘性錶達術後再髮膀胱癌與陰性錶達相比較P>0.05。nm23暘性錶達術後膀胱癌再髮為61.9%(13/21),陰性錶達為20.8%(5/24), P< 0.01。p53、nm23暘性錶達生存率明顯低于陰性錶達,P<0.05。結論:p53 暘性錶達與腎盂輸尿管癌病理分期、分級有關,nm23暘性錶達與術後再髮膀胱癌有關。p53和nm23可能是判斷腎盂輸尿管癌預後的指標之一。
목적:게시p53、nm23 기인표체여신우수뇨관암생물학행위적관계。 방법:채용면역조화SABC법화원위잡교기술검측p53、nm23적표체。결과:신우수뇨관암p53、nm23양성표체분별위51.1%(23/45)화 46.7%(21/45)。p53양성표체T2-T3위60%(21/35),T1위20%(2/10),P<0.05;G2-G3위59.0%(23/39),G1위0%(0/6)。nm23양성표체T2-T3위48.6%(17/35),T1위40%(4/10),P>0.05,G2-G3위 48.7%(19/39),G1위33.3%(2/6),P>0.05。p53양성표체술후재발방광암여음성표체상비교P>0.05。nm23양성표체술후방광암재발위61.9%(13/21),음성표체위20.8%(5/24), P< 0.01。p53、nm23양성표체생존솔명현저우음성표체,P<0.05。결론:p53 양성표체여신우수뇨관암병리분기、분급유관,nm23양성표체여술후재발방광암유관。p53화nm23가능시판단신우수뇨관암예후적지표지일。
Objective:Our aim was to investigate the relationship between the expression of p53,nm23 and biological progress in renal pelvic and ureteral carcinoma. Methods:The expression of p53 was detected by using immunohistochemical SABC method and the expression of nm23 was detected using in situ hybridization. Results:Positive rates of p53 and nm23 in renal pelvis and ureteral carcinoma were 51.1%(23/45),46.7%(21/45)respectively.In T2 to T3 pathological stage,p53 positive rate was 60%(21/35),while it was 20%(2/10) in T1,P<0.05.Positive rate of p53 in G1 to G2 stage was 59%(23/39),and 0%(0/6) in G1.The positive rate of nm23 was 48.6%(17/35) in T2 to T3 stage and 40%(4/10) in T1,P>0.05. In carcinoma of G2 to G3 stage,nm23 was 48.7%(19/39) positive and 33.3%(2/6) in G1,P>0.05.No significant difference was found in the incidence of multi organ urothelial carcinoma between p53,nm23 positive expression group and negative group,P>0.05. The recurrent rates of post operative bladder cancer showed no difference in group of p53 positive expression and negative expression, (P>0.05). Recurrent rate of post operative bladder cancer in nm2 positive group was 61.9%(12/21),and 20.8% in nm23 negative group,P<0.01.Survival rate in p53,nm23 positive expression group was higher than that of negative group,(P<0.01). Conclusion:Positive expression of p53 is related to pathological stage,cellular grade, and prognosis of renal pelvic and ureteral carcinoma.The expression of nm23 is related to the recurence of postoperative bladder cancer,and is helpful in predicating the recurrence of postoperative bladder cancer in renal pelvic and ureteral carcinoma.